Search results
Results from the WOW.Com Content Network
Infant respiratory distress syndrome (IRDS), also known as surfactant deficiency disorder (SDD), [2] and previously called hyaline membrane disease (HMD), is a syndrome in premature infants caused by developmental insufficiency of pulmonary surfactant production and structural immaturity in the lungs.
Severe deficiency of pulmonary surfactant due to disturbed metabolism of any of these proteins can lead to some form of interstitial lung disease in newborns and adults. These conditions share similar pathophysiology and overlapping phenotypes because surfactant gene products interactively communicate and control one another. [ 3 ]
It is characterized by symmetric fine granular opacities, air bronchograms. It does not have pleural effusions because the lung dysfunction is not due to excess fluid (as can occur with a non-compressive Cesaerean section), but decreased surfactant, causing the lungs to be inelastic and crumpled. [6]
Pulmonary surfactant is a surface-active complex of phospholipids and proteins formed by type II alveolar cells. [1] The proteins and lipids that make up the surfactant have both hydrophilic and hydrophobic regions.
Surfactant deficiency is a common cause of respiratory disease. Respiratory distress syndrome (RDS) is a particularly well-known instance of surfactant deficiency because it has a high mortality rate among preterm babies, a variety of other conditions are related to surfactant levels and composition.
John Allen Clements (March 16, 1923 – September 3, 2024) was an American physician and physiologist known for his role in the discovery of pulmonary surfactant, a crucial factor in the development of life-saving treatments for neonatal respiratory distress syndrome. His research revolutionized the care of premature infants, greatly reducing ...
“When systemic and chronic inflammation accompanies these underlying diseases, it can affect multiple organ systems, manifesting as fatigue, muscle weakness, digestive disturbances, joint pain ...
Conditions adult respiratory distress syndrome or Hyaline Membrane Disease are also sometimes treated with exogenously derived surfactant. One of the more common uses of surfactant therapy is to treat alveolar surfactant deficiency in premature newborns. Most commonly, treatment is composed of multiple doses of 100 mg/kg of exogenous surfactant ...